Clinical Trials on Inverse Psoriasis in Japan

Total 120 results

Kyowa Kirin Co., Ltd.

Completed

A Phase 4 Clinical Study of Brodalumab

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK 4827

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
Boehringer Ingelheim

Recruiting

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Generalized Pustular Psoriasis

Japan
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
Amgen

Completed

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

Psoriasis | Psoriatic Arthritis | Psoriasis Arthropatica

Japan
Bristol-Myers Squibb

Recruiting

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (RePhlect)

Plaque Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Coherus Biosciences, Inc.
Shire; Daiichi Sankyo Co., Ltd.

Completed

A Long Term Safety Extension Study (CHS-0214-05)

Rheumatoid Arthritis | Plaque Psoriasis

Japan
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Pfizer

Completed

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Kochi University

Completed

STA-21 Topical Efficacy on Psoriasis

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis

Psoriasis

Japan
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
LEO Pharma
Quintiles, Inc.

Completed

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Recruiting

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK4827

Psoriasis

Japan
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active Psoriatic Arthritis

United States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan

Psoriasis

Japan
Boehringer Ingelheim

Completed

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Psoriasis

Japan
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Minamihanno Hospital

Completed

Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons

Adverse Effects

Japan
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Psoriasis

Japan
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Sun Pharmaceutical Industries Limited

Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of, Italy
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
AbbVie (prior sponsor, Abbott)

Completed

Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

Psoriasis

Japan
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

Plaque Psoriasis

Japan
UCB Biopharma SRL

Active, not recruiting

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Abbott
Eisai Limited

Completed

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Psoriatic Arthritis

United States, Australia, Belgium, Spain, Argentina, China, Canada, Colombia, Czechia, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Taiwan, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Amgen

Completed

Post-Marketing Surveillance Study of OTEZLA

Psoriasis

Japan

3

Subscribe